Horizon Pharma (HZNP) Misses Q1 EPS by 2c, Lowers Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq lags peers as Netflix, chip stocks drag; AmEx lifts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Wall St indexes split, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Jabil falls after placing CEO on paid leave amid internal investigation
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Horizon Pharma (HZNP) PT Lowered to $13 at Citi; Remains Positive on Orphan Drug Valuation and Primary Care Earnings
May 9, 2017 7:40 AM EDTCiti lowered its price target on Horizon Pharma (NASDAQ: HZNP) to $13.00 (from $20.00) while maintaining a Buy rating.
Analyst Liav Abraham said results highlight the structural challenges associated with the companys primary care franchise and they acknowledge the limited visibility.
That... More
Mizuho Securities Downgrades Horizon Pharma (HZNP) to Neutral
May 9, 2017 5:21 AM EDTMizuho Securities downgraded Horizon Pharma (NASDAQ: HZNP) from Buy to Neutral with a price target of $10.00 (from $22.00).
Analyst Irina Koffler cites uncertainty revolving around primary business and the lack of guidance conviction for her downgrade.
FY 2017 EPS estimate falls from $2.11 to $0.66... More
